Pamela Esposito
CIK: 0001744425
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Replimune Launches TUDRIQEV Amidst Mixed Analyst Views. Replimune Group has launched TUDRIQEV, marking a key step in its commercial strategy. Analysts are currently assessing the product's potential, with some suggesting a wait-and-see approach until market performance becomes clearer. The stock is trading near significant support levels, reflecting cautious sentiment as investors evaluate the new launch.
Transaction History
| KYMR | ▲ Buy | Option Exercise | 1,000 | $31K | 5/19/2026 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 2,500 | $123K | 3/20/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 700 | $54K | 3/20/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 600 | $48K | 3/20/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 1,200 | $96K | 3/20/2026 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 2,500 | $123K | 2/20/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 600 | $53K | 2/20/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 1,900 | $165K | 2/20/2026 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 3,000 | $94K | 1/20/2026 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 2,500 | $123K | 1/20/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 400 | $27K | 1/20/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 4,900 | $333K | 1/20/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 200 | $14K | 1/20/2026 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 12,563 | $617K | 12/17/2025 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 12,000 | $332K | 12/17/2025 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 3,000 | $94K | 12/17/2025 | View on chart |
| KYMR | ▼ Sell | Open Market | 14,505 | $1.2M | 12/17/2025 | View on chart |
| KYMR | ▼ Sell | Open Market | 7,959 | $655K | 12/17/2025 | View on chart |
| KYMR | ▼ Sell | Open Market | 4,099 | $342K | 12/17/2025 | View on chart |
| KYMR | ▼ Sell | Open Market | 1,000 | $84K | 12/17/2025 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 5,000 | $148K | 6/3/2025 | View on chart |
| KYMR | ▼ Sell | Open Market | 5,000 | $245K | 6/3/2025 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 2,500 | $74K | 12/2/2024 | View on chart |
| KYMR | ▼ Sell | Open Market | 2,500 | $123K | 12/2/2024 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 8,500 | $251K | 9/17/2024 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 5,000 | $71K | 9/17/2024 | View on chart |
| KYMR | ▼ Sell | Open Market | 6,350 | $303K | 9/17/2024 | View on chart |
| KYMR | ▼ Sell | Open Market | 7,150 | $349K | 9/17/2024 | View on chart |
| REPL | ▲ Buy | Option Exercise | 300 | $990 | 9/12/2023 | View on chart |
| REPL | ▼ Sell | Open Market | 300 | $6K | 9/12/2023 | View on chart |
| REPL | ▲ Buy | Option Exercise | 5,358 | $18K | 9/11/2023 | View on chart |
| REPL | ▼ Sell | Open Market | 5,358 | $107K | 9/11/2023 | View on chart |
| REPL | ▲ Buy | Option Exercise | 13,600 | $45K | 8/22/2023 | View on chart |
| REPL | ▲ Buy | Option Exercise | 5,000 | $78K | 8/22/2023 | View on chart |
| REPL | ▼ Sell | Open Market | 18,600 | $372K | 8/22/2023 | View on chart |
| REPL | ▲ Buy | Option Exercise | 1,400 | $5K | 8/11/2023 | View on chart |
| REPL | ▼ Sell | Open Market | 1,400 | $28K | 8/11/2023 | View on chart |
| REPL | ▲ Buy | Option Exercise | 5,000 | $78K | 7/10/2023 | View on chart |
| REPL | ▼ Sell | Open Market | 17,923 | $388K | 7/10/2023 | View on chart |
| REPL | ▼ Sell | Open Market | 2,077 | $44K | 7/10/2023 | View on chart |
| REPL | ▲ Buy | Option Exercise | 15,000 | $50K | 7/10/2023 | View on chart |
| REPL | ▼ Sell | Open Market | 5,966 | $108K | 5/16/2023 | View on chart |
| REPL | ▲ Buy | Grant | 40,000 | $0 | 4/1/2023 | View on chart |
| REPL | ▲ Buy | Option Exercise | 15,000 | $15K | 12/9/2022 | View on chart |
| REPL | ▼ Sell | Open Market | 15,000 | $375K | 12/9/2022 | View on chart |
| REPL | ▼ Sell | Open Market | 3,507 | $51K | 5/16/2022 | View on chart |
| REPL | ▲ Buy | Grant | 22,750 | $0 | 4/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Raymond James initiates coverage on Kymera with Outperform rating
Raymond James has started covering Kymera Therapeutics, assigning an Outperform rating and a price target of $140. This new analyst note adds to the current consensus, which has an average target of $139.35 from 23 analysts. Recent discussions also question whether the company's pipeline is over-hyped or developing into a major therapeutic success.
Raymond James initiates coverage on Kymera with Outperform rating. Raymond James has started covering Kymera Therapeutics, assigning an Outperform rating and a price target of $140. This new analyst note adds to the current consensus, which has an average target of $139.35 from 23 analysts. Recent discussions also question whether the company's pipeline is over-hyped or developing into a major therapeutic success.